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Background. Influenza A(H7N9) viruses isolated from humans show features suggesting partial adaptation to
mammals. To provide insights into the pathogenesis of H7N9 virus infection, we compared risk factors, clinical presen-
tation, and progression of patients hospitalized with H7N9, H5N1, and 2009 pandemic H1N1 (pH1N1) virus infections.
Methods. We compared individual-level data from patients hospitalized with infection by H7N9 (n = 123), H5N1
(n = 119; 43 China, 76 Vietnam), and pH1N1 (n = 3486) viruses. We assessed risk factors for hospitalization after ad-
justment for age- and sex-specific prevalence of risk factors in the general Chinese population.
Results. The median age of patients with H7N9 virus infection was older than other patient groups (63 years;
P < .001) and a higher proportion was male (71%; P < .02). After adjustment for age and sex, chronic heart disease
was associated with an increased risk of hospitalization with H7N9 (relative risk, 9.68; 95% confidence interval,
5.24–17.9). H7N9 patients had similar patterns of leukopenia, thrombocytopenia, and elevated alanine aminotransfer-
ase, creatinine kinase, C-reactive protein, and lactate dehydrogenase to those seen in H5N1 patients, which were all sig-
nificantly different from pH1N1 patients (P < .005). H7N9 patients had a longer duration of hospitalization than either
H5N1 or pH1N1 patients (P < .001), and the median time from onset to death was 18 days for H7N9 (P = .002) vs 11
days for H5N1 and 15 days for pH1N1 (P = .154).
Conclusions. The identification of known risk factors for severe seasonal influenza and the more protracted clinical
course compared with that of H5N1 suggests that host factors are an important contributor to H7N9 severity.
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The emergence of human infections with avian influenza A
(H7N9) virus further widens the spectrum of novel influenza
A viruses that currently pose a threat to public health [1]. Al-
though H7N9 virus has not been shown to transmit efficiently
between humans, there are indications that the recently emerged
H7N9 viruses are better adapted to replication in mammalian
cells than other avian influenza A viruses and represent a plausi-
ble pandemic threat [2, 3]. H7N9 viruses isolated from human
cases have amino acid sequences in the hemagglutinin (HA) pro-
tein that are associated with improved binding to α2–6-linked
sialidases that are abundant on human respiratory epithelial
cells, and in the polymerase and other proteins that are associated
with increased virulence and transmissibility in mammals [2–4].
In ferret experiments, H7N9 virus replicates well in the upper
respiratory tract following intranasal inoculation, causes rela-
tively mild illness, and is efficiently transmitted by direct con-
tact, but less so by respiratory droplets [2, 3, 5]. Intratracheal
inoculation of ferrets results in severe pneumonia and high
mortality [6]. In a ferret model, therefore, H7N9 virus possesses
a constellation of features that are intermediate between highly
pathogenic H5N1 viruses and fully adapted but less virulent
human influenza A viruses such as influenza A subtypes
H3N2 and pandemic H1N1/2009 (pH1N1).
Despite meeting the criteria for a low pathogenic phenotype
in birds, H7N9 virus has caused severe and fatal disease in hu-
mans [7]. However, the demographic profile of patients with
H7N9 virus infection is unusual, with a high median age and
an excess of males [8]. Although this might be due to age and
sex differences in exposures to infected poultry or settings contam-
inated by infected poultry, the pattern differs markedly from
H5N1 cases, and would also be consistent with age-dependent
biological cofactors contributing to pathogenesis and disease
severity [8]. An assessment of the clinical severity of human in-
fections with H7N9 virus has concluded that many mild cases
may have occurred and the overall symptomatic case fatality
risk is estimated to be <3% [7]. Understanding the determinants
of the severity of disease due to H7N9 virus infection is impor-
tant both for the identification and clinical management of
high-risk cases and for the purposes of public health risk assess-
ment and contingency planning.
To assess whether the H7N9 virus genotype translates into a
distinct clinical phenotype in humans, and to provide insights
into the pathogenesis of H7N9 virus infection, we compared the
risk factors, clinical presentation, and progression of patients
hospitalized with H7N9, H5N1, and pH1N1 virus infections.
METHODS
Subject Ascertainment
All subjects with influenza virus infection reported in this man-
uscript were hospitalized patients. The patients with laboratory-
confirmed H7N9 infection were all hospitalized in China
between 25 February and 4 May 2013. The Chinese H5N1
cases represent all hospitalized cases of laboratory-confirmed
H5N1 virus infection detected between 30 November 2003
and 8 February 2012. The Vietnamese H5N1 cases represent
all hospitalized cases of laboratory-confirmed H5N1 virus infec-
tion detected between 25 December 2003 and 14 March 2009
[9]. A comparison of the Chinese and Vietnamese H5N1
cases showed similar demographic characteristics, underlying
medical conditions, and behavioral risk factors (Supplementary
Data). Patients with pH1N1 virus infection in China were ascer-
tained through hospitals designated for the treatment of severe
cases. The case definitions and time periods for ascertaining pa-
tients hospitalized with influenza A H5N1, H7N9, and pH1N1
virus infections are available in the Supplementary Data.
Clinical and laboratory data were abstracted retrospectively
from original medical records for cases of H7N9, H5N1, and
pH1N1 virus infections. Laboratory values were presented as
medians with interquartile ranges and were dichotomized into
normal or abnormal based on normal ranges for children and
adults (Supplementary Table 1). Because the only subjects aged
<29 days were 5 subjects with pH1N1 virus infection, and normal
laboratory values are different in neonates compared with other
age groups, we excluded all subjects aged <29 days from the as-
sessment of laboratory results. We excluded pH1N1 cases from
the analysis of signs and symptoms on admission as the ascer-
tainment process for these cases required the presence of 1 or
more symptoms, many of which were severe.
Ethics Statement
The Chinese National Health and Family Planning Commis-
sion determined that the collection of data from H5N1,
H7N9, and pH1N1 cases was part of public health investiga-
tions of emerging influenza outbreaks and was exempt from in-
stitutional review board assessment. The Science and Ethics
Committee of the Ministry of Science and Technology of Viet-
nam approved the collection of clinical data from Vietnamese
subjects with H5N1 virus infection.
Risk Factors for Hospitalization and Death
To assess the importance of putative risk factors for hospitaliza-
tion with each influenza A subtype, we estimated the relative
risk of being hospitalized in subjects with and without risk fac-
tors. Data on the prevalence of each risk factor in the general
Chinese population were used as denominators for the risk es-
timates and to weight (adjust) the overall relative risk estimates
by age and sex. Data on age- and sex-specific population prev-
alence were available for coronary heart disease, chronic renal
disease, diabetes, hypertension, smoking, and obesity; age-
specific but not sex-specific population prevalence was available
for asthma and chronic obstructive pulmonary disease (COPD)
1096 • CID 2014:58 (15 April) • Wang et al
 at U
niversity of H
ong K
ong on A
pril 8, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
[10–13]. The definitions for these conditions are shown in the
Supplementary Data. The age- and sex-stratified population
prevalence of chronic heart disease (CHD; excluding isolated
hypertension) was estimated from a study that recorded a
prior history of hospitalization with coronary artery disease
(A history of hospitalization for myocardial infarction or a sur-
gical history of coronary balloon angioplasty, or coronary stent
implantation or coronary artery bypass.) [10]. We assumed that
the age distribution of coronary artery disease is a valid proxy
for the age distribution of CHD. Where surveys assessed disease
prevalence only in older adults, we assumed that prevalence was
zero in those younger than the lower age limit of the survey. Be-
cause we were not able to source relevant baseline data for Viet-
nam, we have assumed that the age distribution of chronic
diseases is similar in the Chinese and Vietnamese populations.
Statistical Methods
We compared the characteristic of patients infected by different
subtypes using Fisher exact test or χ2 test for comparing propor-
tions and Wilcoxon signed-rank test for comparing medians of
continuous variables. To evaluate the association between risk
factors and the risk of hospitalization, Poisson regression was
used to estimate the incidence rate ratios associated with each
risk factor, adjusted for age and sex. The association between
risk factors and the risk of death among hospitalized cases
was assessed using multivariable logistic regression to estimate
the odds ratios associated with each risk factor, adjusted for age
and sex. In both analyses a spline function was used for age to
allow for the possibly nonlinear effect of age on risk.
We used the Kaplan-Meier method to estimate survival curves
for death and the hospitalized fatality risk. We used the same ap-
proach to estimate the time to invasive mechanical ventilation. The
censoring time of each recovered or nonventilated patient was set to
90 days. The 95% confidence intervals (CIs) for the cumulative pro-
portion of subjects requiring invasive ventilation and with a fatal
outcome were estimated using bootstrapping with 1000 resamples.
We used maximum likelihood to estimate the distribution of
the number of days of hospitalization, and compared alternative
parametric distributions including γ, Weibull, and log-normal
distributions, selecting the best parametric distribution on the
basis of the Akaike information criterion.
RESULTS
As of 6 August 2013, 133 laboratory-confirmed influenza
A(H7N9) cases have been officially recorded in mainland
China. Among these, 123 requiring hospitalization for medical
reasons were included in this study [7]. Ten laboratory-
confirmed mild cases were excluded [14]. Data were included
for 119 patients hospitalized with H5N1 (Vietnam = 76;
China = 43), and 3486 patients hospitalized with pH1N1.
The median age of subjects hospitalized with H7N9 was
63 years, compared to 26 years for H5N1 patients and
Table 1. Characteristics of Subjects Hospitalized With Influenza A Virus Subtypes H7N9, H5N1, and pH1N1
Characteristic H7N9a H5N1 P Value pH1N1 P Value
Age, y, median (range) 63 (4–91) 26 (1–75) <.001 25 (0–100) <.001
Interval from onset, admission days (IQR) 4 (3–6) 5 (3–6) .155 4 (3–6) .244
Male sex 87/123 (71%) 67/119 (56%) .019 1937/3486 (56%) .001
Any coexisting chronic medical conditions 42/105 (40%) 11/104 (11%) <.001 748/3485 (21%) <.001
Chronic heart disease 12/105 (11%) 1/102 (1%) .001 147/3457 (4%) .003
Chronic lung disease 10/105 (10%) 6/100 (6%) .344 305/3397 (9%) .849
Chronic renal disease 1/105 (1%) 1/102 (1%) .984 91/3450 (3%) .221
Chronic liver disease 5/105 (5%) 1/101 (1%) .092 27/3478 (1%) .002
Chronic neurological disease 3/105 (3%) 0/39 (0%) .166 55/3472 (2%) .356
Diabetes 18/105 (17%) 1/100 (1%) <.001 185/3470 (5%) <.001
Asthma 0/105 (0%) 0/0 NA 102/3442 (3%) .013
Immune compromise 2/105 (2%) 1/100 (1%) .586 86/3433 (3%) .685
Hypertension 51/105 (49%) 2/41 (5%) <.001 366/3479 (11%) <.001
Malignancy 6/105 (6%) 1/41 (2%) .375 92/3468 (3%) .096
Pregnancy 2/105 (2%) 5/106 (5%) .246 400/3436 (12%) <.001
Smoking history 26/105 (25%) 10/88 (11%) .015 541/3431 (16%) .02
Obesity (BMI ≥30) 3/45 (7%) 0/10 (0%) .265 175/2018 (9%) .623
Any coexisting chronic medical conditions are any of the following: asthma, diabetes, chronic respiratory disease, chronic heart disease, chronic renal disease,
chronic hepatic (liver) disease, chronic neurological disease, immune compromise (see Supplementary Data for definitions).
Abbreviations: BMI, body mass index; IQR, interquartile range; pH1N1, 2009 pandemic H1N1 virus.
a Reference group.
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25 years for pH1N1 patients (P < .001). A higher proportion of
H7N9 subjects were male compared with H5N1 (P = .019) or
pH1N1 subjects (P = .001). Subjects hospitalized with H7N9
had the highest prevalence of chronic medical conditions tradi-
tionally associated with an increased risk of severe seasonal
influenza disease (Table 1). CHD and diabetes were the com-
monest medical risk factors reported among H7N9 patients,
and the prevalence of smoking and hypertension was higher
in subjects with H7N9 compared with the other patient groups.
Pregnancy was more common in subjects hospitalized with
pH1N1.
Compared with subjects without CHD, the presence of CHD
was associated with an increased risk of hospitalization with
H7N9 (relative risk [RR], 9.68; 95% CI, 5.24–17.9; Table 2).
CHD was also a risk factor for hospitalization with pH1N1
(RR, 16.51; 95% CI, 13.68–19.91). Hypertension was not asso-
ciated with an increased risk of hospitalization in any group,
whereas a history of smoking was associated with a reduced
risk of hospitalization. Chronic renal disease was associated
with a reduced risk of hospitalization in H7N9 and pH1N1
patients. Once patients were hospitalized, the odds of death
were not significantly increased in subjects with any of the
risk factors examined (Table 3).
Signs and symptoms at hospital admission were compared
for H7N9 and H5N1 cases. Subjects with H7N9 virus infection
were more likely to report a fever, a productive cough, and
hemoptysis than those with H5N1 virus infection (Table 4).
Gastrointestinal symptoms were most common in H5N1 cases.
The values of hematological, liver, and renal function tests, and
markers of inflammation on admission are shown in Table 5.
Table 2. Age- and Sex-Adjusted Risk Factors for Hospitalization
Risk Factora
Source of Baseline
Prevalence Data
H7N9 H5N1 pH1N1
RR (95% CI)b RR (95% CI)b RR (95% CI)b
Asthmac [12, 15] NC NC 1.76 (1.43–2.15)
COPDc (assume zero prevalence aged <40 y) [11] 0.73 (.35–1.52) 4.25 (1.34–13.48) 1.76 (1.43–2.18)
Diabetes (assume zero prevalence aged <20 y) [10] 1.11 (.67–1.87) 0.23 (.03–1.67) 1.11 (.94–1.30)
Chronic heart disease (assume zero prevalence aged <20 y) [10] 9.68 (5.24–17.9) NC 16.51 (13.68–19.91)
Chronic renal disease (assume zero prevalence aged <18 y) [13] 0.07 (.01–.54) NC 0.47 (.37–.58)
Hypertension (assume zero prevalence aged <20 y) [10] 1.28 (.85–1.91) 0.45 (.10–1.99) 0.63 (.55–.71)
Smokingd [10] 0.38 (.24–.60) 0.41 (.20–.88) 0.74 (.66–.84)
Obesity (BMI ≥30)c [10] 1.16 (.36–3.74) NC 2.42 (2.03–2.88)
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; NC, not calculable due to insufficient data; RR, relative
risk.
a See the Supplementary Data for definitions.
b Adjusted for cubic spline for age (continuous) and sex where data were available.
c Sex-specific data not available.
d Restricted to subjects aged ≥20 years only.
Table 3. Age- and Sex-Adjusted Risk Factors for Death Among Hospitalized Patients
Risk Factora
H7N9 H5N1 pH1N1
Deathb, OR (95% CI) Deathb, OR (95% CI) Deathb,OR (95% CI)
Asthma NC NC 0.24 (.06–1.01)
COPD 2.55 (.38–17.20) 0.92 (.12–6.83) 0.98 (.51–1.89)
Diabetes 3.68 (.97–14.03) NC 0.85 (.51–1.44)
Chronic heart disease 0.96 (.18–5.17) NC 1.22 (.72–2.08)
Chronic renal disease NC NC 1.56 (.86–2.80)
Hypertension 1.06 (.36–3.13) 0.24 (.01–6.92) 0.87 (.58–1.29)
Smoking 0.66 (.20–2.17) 1.23 (.25–5.99) 1.12 (.79–1.60)
Obesity (BMI ≥30) NC NC 0.96 (.59–1.56)
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; NC, not calculable due to insufficient data; OR, odds
ratio.
a See Supplementary Data for definitions.
b Adjusted for cubic spline for age (continuous) and sex.
1098 • CID 2014:58 (15 April) • Wang et al
 at U
niversity of H
ong K
ong on A
pril 8, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
H7N9 and H5N1 patients showed similar patterns of elevated
alanine aminotransferase, creatinine kinase, C-reactive protein,
and lactate dehydrogenase, which were all significantly higher
than in pH1N1 patients. Leukopenia and thrombocytopenia
were equally common in patients with H7N9 and H5N1 virus
infections, and more common than in those with pH1N1 virus
infection. Lymphopenia was more common in patients with
H7N9 compared with H5N1 (88% vs 55%; P < .001), and neu-
tropenia was more common in H5N1 patients. Neutrophilia
was equally common in H5N1 and pH1N1 patients, and least
common in H7N9 patients.
The risk of invasive ventilation and death among hospitalized
cases by influenza A virus subtype are shown in Figure 1. The
cumulative proportion of hospitalized subjects requiring inva-
sive ventilation differs between subtypes, reaching 62% (95%
CI, 53%–71%) for H7N9, 54% (95% CI, 45%–63%) for H5N1,
and 17% (95% CI, 15%–18%) for pH1N1. Among those venti-
lated, the interval from onset to invasive ventilation was a me-
dian of 7 days for both H7N9 and H5N1 cases (P = .651), and 6
days for pH1N1 cases. The hospitalized case fatality risk was
highest for H5N1 (55%; 95% CI, 47%–64%) and death occurred
earlier, with a median time from onset to death of 11 days for
Table 5. Laboratory Results on Admissiona
Result H7N9b H5N1 P Value pH1N1 P Value
White cell count 4.5 (2.9–6.2) 3.9 (2.5–7.1) .805 6 (4.2–8.8) <.001
Lymphocyte count 0.5 (0.3–0.7) 0.9 (0.6–1.4) <.001 1 (0.6–1.5) <.001
Neutrophil count 3.3 (2.2–5.4) 3 (1.5–5.4) .203 4.3 (2.6–6.9) .004
Platelet count 114 (82–147.5) 126 (86–196) .203 173 (132–229.8) .004
AST 53 (38–96.5) 100 (47–233) .076 40 (26.4–68.5) <.001
ALT 35.5 (24–64.5) 48.5 (29.5–99.5) <.001 24 (15.6–44) <.001
Serum creatinine 70.7 (58.3–85) 83 (54–100) .028 62 (45.4–81) <.001
CK 195 (96–562) 552 (126.5–939.8) .255 120 (62–304) <.001
CRP 65 (25–113) 51 (14.2–118.3) .191 25.4 (7.9–75.5) <.001
LDH 498 (388–661) 1025 (334.8–1832.5) .525 307 (217–491) <.001
Leukopenia 48/105 (46%) 54/107 (50%) .489 736/3305 (22%) <.001
Lymphopenia 88/99 (89%) 54/98 (55%) <.001 1601/2891 (55%) <.001
Neutropenia 13/103 (13%) 24/97 (25%) .027 221/2891 (8%) .086
Neutrophilia 5/103 (5%) 15/97 (15%) .011 477/2891 (16%) <.001
Thrombocytopenia 80/104 (77%) 69/105 (66%) .073 1106/3066 (36%) <.001
Elevated AST 54/103 (52%) 41/54 (76%) .004 1165/3197 (36%) .001
Elevated ALT 34/100 (34%) 25/52 (48%) .093 668/3167 (21%) .003
Elevated serum creatinine 11/103 (11%) 9/62 (15%) .469 201/3054 (7%) .129
Elevated CK 48/98 (49%) 13/20 (65%) .188 1018/2951 (34%) .004
Elevated CRP 83/92 (90%) 9/12 (75%) .162 1193/1708 (70%) <.001
Elevated LDH 89/98 (91%) 17/21 (81%) .218 1617/2922 (55%) <.001
Data are presented as median (IQR) or No. (%).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; CRP, C-reactive protein; IQR, interquartile range; LDH, lactate
dehydrogenase; pH1N1, 2009 pandemic H1N1 virus.
a Or earliest available time point after admission.
b Reference group.
Table 4. Signs and Symptoms on Admissiona
Sign or Symptom H7N9 H5N1
P
Value
Fever (temp ≥37.8) 99/105 (94%) 75/102 (74%) <.001
Any cough 96/105 (91%) 89/106 (84%) .097
Productive cough 59/104 (57%) 35/94 (37%) .006
Dry cough 17/105 (16%) 45/94 (48%) <.001
Yellow sputum 33/105 (31%) 10/61 (16%) .029
Hemoptysis 25/105 (24%) 5/61 (8%) .008
Myalgia 21/105 (20%) 12/50 (24%) .572
Fatigue 38/105 (36%) 9/37 (24%) .179
Shortness of breath 62/105 (59%) 54/93 (58%) .889
Gastrointestinal
symptoms
15/105 (14%) 17/53 (32%) .01
Diarrhea 10/105 (10%) 6/50 (12%) .64
Vomiting 4/105 (4%) 10/54 (19%) .003
Nausea 6/105 (6%) 7/50 (14%) .093
Central nervous system
symptoms
4/105 (4%) 8/113 (7%) .285
a Or earliest available time point after admission.
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H5N1, compared with 15 days for pH1N1 patients (P = .154)
and 18 days for H7N9 (P = .002). H7N9 patients were hospital-
ized for a longer duration than either H5N1 (P < .001) or
pH1N1 patients (P < .001) (Figure 2).
DISCUSSION
One of the most striking differences in this and other compar-
ative analysis is the high median age of H7N9 patients [16].This
age distribution is unlikely to be due to differences in humoral
immunity as the prevalence of neutralizing antibodies to H7N9
virus is probably low in all ages [17–20]. It might arise either
because elderly people are more often exposed to the animal
or environmental reservoir of H7N9 viruses, or because elderly
people have a greater propensity to become infected or sever-
ely ill following exposure. After adjusting for the age- and
sex-specific prevalence of chronic illnesses in the general Chi-
nese population, we found that CHD was associated with an in-
creased risk of hospitalization with H7N9 virus infection (RR,
9.68; 95% CI, 5.24–17.9). The age distribution of H7N9 patients
may therefore be partially explained by an increased propensity
in persons with CHD (who are mostly older) to develop severe
disease following infection with H7N9 virus. The overrepresen-
tation of males among H7N9 patients may also be partially
explained by this association, because in China coronary heart
disease is commoner in males than females (male prevalence,
Figure 1. Case fatality risk and invasive ventilation risk in hospitalized patients. A and B, Case fatality risk by influenza A virus subtype and day of
hospitalization (A) and day of illness onset (B). C and D, Invasive ventilation risk by influenza A virus subtype and day of hospitalization (C) and day of
illness onset (D). Abbreviation: pH1N1, 2009 pandemic H1N1 virus.
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0.74%; female prevalence, 0.51%) [10]. In agreement with our
results, an age- and sex-matched case control study of 25
H7N9 cases has reported that the presence of a preexisting
chronic medical condition (excluding hypertension) was associ-
ated with H7N9 disease (odds ratio, 5.1; 95% CI, 1.5–16.9) [21].
Although only 11% of H7N9 patients reported a history of
CHD, unrecognized CHD may have been present in some
individuals, and other unmeasured age-related factors, such as
impaired innate and cell-mediated immunity, might also con-
tribute to the observed age distribution of hospitalized H7N9
cases [17, 22, 23]. H7N9 viruses isolated from humans exhibit
a mixed receptor specificity, binding both α2–6- and α2–3-
linked sialidases [3, 4, 20]. H7N9 virus can infect cells of both
the upper and lower respiratory tract of humans and ferrets,
and disease in ferrets is more severe following intratracheal in-
oculation [5, 6, 20]. This raises the possibility that susceptibility
of humans to severe H7N9 disease may be a consequence of
an impaired ability to control virus replication in the lower
respiratory tract.
A history of chronic renal disease was associated with a
reduced risk of hospitalization with H7N9 virus infection, but
the number of patients with this condition was small, so this
finding should be interpreted with caution. A history of smok-
ing was associated with a reduced risk of hospitalization with
H7N9, H5N1, and pH1N1 virus infections. This is an unexpect-
ed finding that might be biased by inconsistent definitions and
methods of ascertaining smoking history, which were not stan-
dardized in the clinical datasets.
The clinical presentation and laboratory indices at hospital
admission are similar for H7N9 and H5N1 patients, except
that a productive cough, hemoptysis, lymphopenia, and neutro-
penia were more common in H7N9 patients. Neutropenia,
thrombocytopenia, and elevated liver enzymes are common in
H5N1 patients and have been associated with more severe
outcomes [9, 24–29]. A low absolute lymphocyte count has
been associated with poor outcomes in patients hospitalized
with pH1N1, H5N1, and severe acute respiratory syndrome
[9, 30–32]. The hematological and serum chemistry abnormal-
ities suggest that subjects hospitalized with H7N9 have a severe
systemic illness. It remains to be determined if this is a conse-
quence of severe pneumonia and poor tissue oxygenation or is
the result of an excessive inflammatory response (as is seen with
H5N1 virus infection) [33]. High levels of chemokines and cy-
tokines have been identified in patients with H7N9 virus infec-
tion [20]. Extrapulmonary virus replication is an alternative
explanation for the severity of hospitalized H7N9 cases, but
H7N9 virus does not posses the polybasic amino acid motif at
the HA cleavage site normally associated with extrapulmonary
virus replication, and experimental H7N9 virus infection of fer-
rets has provided little evidence of systemic replication [2, 34,
35]. H7N9 viral RNA has been detected in the serum, urine,
and feces of H7N9 patients but it is not known if this represents
viral replication occurring outside of the respiratory tract [35].
Hospitalized H7N9 patients had a case fatality risk that was
intermediate between pH1N1 and H5N1 patients, and a more
protracted clinical course than either H5N1 or pH1N1 patients,
with the longest median time to death and the longest hospital-
ization. Whether this reflects the natural history of severe H7N9
virus infection, patient characteristics, or differences in the
clinical management of patients with severe H7N9 compared
with H5N1 patients, including increased frequency of rescue
modalities such as extracorporeal membrane oxygenation, is
unknown.
The comparisons we have made are limited by a lack of
standardization of the methods of case ascertainment and in-
clusion, and of the recording of clinical and other data. As
such, the patients and data included in this study may be subject
to unmeasured selection and information biases and differences
in practices over time and between locations. However, we have
tried to minimize these potential biases by restricting our anal-
ysis only to hospitalized subjects and to variables where data
were available for a reasonable proportion of all cases. Although
the H5N1 patients from China and Vietnam had very similar
demographic characteristics, underlying medical conditions,
and behavioral risk factors, there were some differences in clin-
ical presentation (Supplementary Data), and we cannot exclude
that the clinical phenotype of H5N1 virus infections may be
heterogeneous. We used univariate analysis that adjusted for
age and sex to explore possible risk factors for hospitalization
with H7N9; interactions effects were not assessed and the esti-
mated odds ratios and RRs might be confounded by other
Figure 2. Distribution of the number of days of hospitalization for pa-
tients with H7N9, H5N1, and pH1N1.
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unmeasured confounders; as such, these risk factors should not
be considered to be causal without further validation.
In conclusion, this comparative analysis shows that patients
hospitalized with H7N9 virus infection share some risk factors
with those hospitalized with pH1N1 infection but have a clini-
cal profile more closely resembling that of H5N1 patients. The
identification in H7N9 patients of known risk factors for severe
seasonal influenza and the more protracted clinical course com-
pared with H5N1 patients suggests that host factors may be an
important contributor to the severity of H7N9 virus infection.
This is consistent with the observation that there have probably
been a large number of undetected mild H7N9 virus infections,
and to date the patients with detected mild infection have been
predominantly young (mean age, 13 years) [7, 14]. H7N9 virus
has recently reemerged in China. People with chronic medical
conditions that are traditionally associated with a higher risk of
severe complications following seasonal influenza virus infec-
tion should be targeted for preventive interventions and for
early treatment with antiviral drugs should they develop a respi-
ratory illness.
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